Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms

被引：0
|
作者：
Fan, Y. [1 ]
Xu, Y. [1 ]
Tong, X. [2 ]
Yan, J. [3 ]
Wu, X. [2 ]
Shao, Y. W. [2 ]
机构：
[1] Zhejiang Canc Hosp, Key Lab Diag & Treatment Technol Thorac Canc, Hangzhou, Zhejiang, Peoples R China
[2] Geneseeq Technol Inc, Translat Med Res Inst, Toronto, ON, Canada
[3] Nanjing Geneseeq Technol Inc, Med Dept, Nanjing, Jiangsu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
157P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [42] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [43] Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors
    Kuiper, Justine L.
    Smit, Egbert F.
    ONCOLOGY, 2014, 87 (02) : 83 - 94
  • [44] Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Iommelli F.
    De Rosa V.
    Fonti R.
    Del Vecchio S.
    Clinical and Translational Imaging, 2014, 2 (1) : 43 - 53
  • [45] Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer
    Liao, Zi-Xian
    Huang, Kuo-Yen
    Kempson, Ivan M.
    Li, Hsin-Jung
    Tseng, S. -Ja
    Yang, Pan-Chyr
    JOURNAL OF CONTROLLED RELEASE, 2020, 324 : 482 - 492
  • [46] PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
    Jin, Guang
    Kim, Min Jung
    Jeon, Hyo-Sung
    Choi, Jin Eun
    Kim, Dong Sun
    Lee, Eung Bae
    Cha, Sung Ick
    Yoon, Ghil Sook
    Kim, Chang Ho
    Jung, Tae Hoon
    Park, Jae Yong
    LUNG CANCER, 2010, 69 (03) : 279 - 283
  • [47] Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients.
    Marchetti, Antonio
    Palma, John F.
    Felicioni, Lara
    De Pas, Tommaso Martino
    Chiari, Rita
    Del Grammastro, Maela
    Filice, Giampaolo
    Ludovini, Vienna
    Brandes, Alba Ariela
    Chella, Antonio
    Malorgio, Francesco
    Guglielmi, Flavio
    De Tursi, Michele
    Santoro, Armando
    Crino, Lucio
    Buttitta, Fiamma
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
    Singh, Mahaveer
    Jadhav, Hemant R.
    DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
  • [49] Polymorphisms in Apoptosis-Related Genes and TP53 Mutations in Non-Small Cell Lung Cancer
    Bae, Eun Young
    Lee, Eun Jin
    Kang, Hyo-Gyoung
    Lee, Shin Yup
    Jin, Gwang
    Lee, Won Kee
    Choi, Jin Eun
    Jeon, Hyo-Sung
    Lim, Jeong Ok
    Lee, Eung Bae
    Park, Jae Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (11) : 1527 - 1530
  • [50] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    A F Gazdar
    Oncogene, 2009, 28 : S24 - S31
12345